Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain, and shortness of breath. Causes include cardiomyopathy, ischemic heart disease, and heart failure. Risk factors include age, family history, and medical history. Treatment includes antiarrhythmic medication.
The Ventricular Tachycardia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects.
Ventricular Tachycardia Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Ventricular Tachycardia pipeline drugs market are Beta 1 Adrenergic Receptor, Calcium Channel, Alpha 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Ion Channel, Peptidyl Prolyl Cis Trans Isomerase FKBP1A, Potassium Channel, Potassium Voltage Gated Channel Subfamily H Member 2, Ryanodine Receptor, and Ryanodine Receptor 2.
Ventricular Tachycardia Pipeline Drugs Market Analysis, by Targets
For more Ventricular Tachycardia pipeline drugs market target insights, download a free report sample
Ventricular Tachycardia Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanisms of action of the Ventricular Tachycardia pipeline drugs market are Beta 1 Adrenergic Receptor Antagonist, Calcium Channel Blocker, Alpha 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Ion Channel Blocker, Peptidyl Prolyl Cis Trans Isomerase FKBP1A Inhibitor, Potassium Channel Blocker, Potassium Voltage Gated Channel Subfamily H Member 2 Blocker, Ryanodine Receptor 2 Antagonist, Sodium Channel Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker.
Ventricular Tachycardia Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the Ventricular Tachycardia pipeline drugs market, download a free report sample
Ventricular Tachycardia Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Ventricular Tachycardia pipeline drugs market are oral, inhalational, intravenous, and nasal.
Ventricular Tachycardia Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Ventricular Tachycardia pipeline drugs market, download a free report sample
Ventricular Tachycardia Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Ventricular Tachycardia pipeline drugs market are Small Molecule and Gene Therapy.
Ventricular Tachycardia Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Ventricular Tachycardia pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the Ventricular Tachycardia pipeline drugs market are ARMGO Pharma Inc, Academic Pharmaceuticals Inc, Elex Biotech LLC, GEXVal Inc, HUYA Bioscience International LLC, InCarda Therapeutics Inc, Milestone Pharmaceuticals Inc, Saliogen Therapeutics Inc, and Vivasc Therapeutics Inc.
Ventricular Tachycardia Pipeline Drugs Market Analysis, by Companies
To know more about the Ventricular Tachycardia pipeline drugs market companies, download a free report sample
Ventricular Tachycardia Pipeline Drugs Market Report Overview
Key Targets | Beta 1 Adrenergic Receptor, Calcium Channel, Alpha 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Ion Channel, Peptidyl Prolyl Cis Trans Isomerase FKBP1A, Potassium Channel, Potassium Voltage Gated Channel Subfamily H Member 2, Ryanodine Receptor, and Ryanodine Receptor 2 |
Key Mechanism of Actions | Beta 1 Adrenergic Receptor Antagonist, Calcium Channel Blocker, Alpha 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Ion Channel Blocker, Peptidyl Prolyl Cis Trans Isomerase FKBP1A Inhibitor, Potassium Channel Blocker, Potassium Voltage Gated Channel Subfamily H Member 2 Blocker, Ryanodine Receptor 2 Antagonist, Sodium Channel Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker |
Key Routes of Administration | Oral, Inhalational, Intravenous, and Nasal |
Key Molecule Types | Small Molecule and Gene Therapy |
Key Companies | ARMGO Pharma Inc, Academic Pharmaceuticals Inc, Elex Biotech LLC, GEXVal Inc, HUYA Bioscience International LLC, InCarda Therapeutics Inc, Milestone Pharmaceuticals Inc, Saliogen Therapeutics Inc, and Vivasc Therapeutics Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Ventricular Tachycardia.
- Reviews of pipeline therapeutics for Ventricular Tachycardia by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews key companies involved in Ventricular Tachycardia therapeutics and enlists all their major and minor projects.
- Evaluation of Ventricular Tachycardia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Ventricular Tachycardia.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ventricular Tachycardia.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ventricular Tachycardia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
ARMGO Pharma Inc
Elex Biotech LLC
GEXVal Inc
HUYA Bioscience International LLC
InCarda Therapeutics Inc
Milestone Pharmaceuticals Inc
Saliogen Therapeutics Inc
Vivasc Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Ventricular Tachycardia pipeline drugs market?
Some of the key targets of the Ventricular Tachycardia pipeline drugs market are the Beta 1 Adrenergic Receptor, Calcium Channel, Alpha 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Ion Channel, Peptidyl Prolyl Cis Trans Isomerase FKBP1A, Potassium Channel, Potassium Voltage Gated Channel Subfamily H Member 2, Ryanodine Receptor, and Ryanodine Receptor 2.
-
What are the key mechanisms of action in the Ventricular Tachycardia pipeline drugs market?
Some of the key mechanisms of action in the Ventricular Tachycardia pipeline drugs market are Beta 1 Adrenergic Receptor Antagonist, Calcium Channel Blocker, Alpha 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Ion Channel Blocker, Peptidyl Prolyl Cis Trans Isomerase FKBP1A Inhibitor, Potassium Channel Blocker, Potassium Voltage Gated Channel Subfamily H Member 2 Blocker, Ryanodine Receptor 2 Antagonist, Sodium Channel Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker.
-
What are the key routes of administration in the Ventricular Tachycardia pipeline drugs market?
The key routes of administration in the Ventricular Tachycardia pipeline drugs market are oral, inhalational, intravenous, and nasal.
-
What are the key molecule types in the Ventricular Tachycardia pipeline drugs market?
The molecule types in the Ventricular Tachycardia pipeline drugs market are Small Molecule and Gene Therapy.
-
Which are the key companies in the Ventricular Tachycardia pipeline drugs market?
Some of the key companies in the Ventricular Tachycardia pipeline drugs market are ARMGO Pharma Inc, Academic Pharmaceuticals Inc, Elex Biotech LLC, GEXVal Inc, HUYA Bioscience International LLC, InCarda Therapeutics Inc, Milestone Pharmaceuticals Inc, Saliogen Therapeutics Inc, and Vivasc Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.